Farrukh T Awan, MD
College of Medicine
Leukemia, Lymphocytic, Chronic, B-Cell, Cancer, Multiple Myeloma, Nausea, Thrombocytopenia, Lymphoma, Lymphoma, Mantle-Cell, Leukemia, Myeloid, Acute, Lymphoma, Follicular, Graft vs Host Disease
Farrukh Tauseef Awan, MD, MS, is a member of the Leukemia Research Program at the OSUCCC – James, where he is a medical oncologist who treats patients with leukemia and other blood cancers. He has specific expertise in chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and non-Hodgkin lymphoma (NHL).
Dr. Awan’s recent research includes integrating therapeutics that target tumor-survival pathways with agents that reverse immune tolerance to facilitate long-term remission or cure. He also recently co-led an effort to study the pre-clinical and clinical activity of monalizumab, which targets HLA-E-NKG2A interaction, in patients with CLL.
Dr. Awan has co-authored dozens of articles in well-respected publications, including New England Journal of Medicine, Blood, Journal of Clinical Oncology, British Journal of Haematology, Leukemia and Clinical Cancer Research.
In addition, he has co-presented his research at national and international events, including the Congress of the European Hematology Association, the American Society of Clinical Oncology annual meeting and the American Society of Hematology annual meeting.